Latest Financials News

Antilles Gold initiates a $650,000 share placement to fund working capital and prepare for a major $29.5 million EPC contract with Xinhai Mining, advancing the Nueva Sabana copper-gold mine development in Cuba.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

Coventry Group’s FY25 results reveal a sharp EBITDA decline amid ERP disruptions and soft markets, prompting a major cost reduction drive for FY26.

Macro Metals Limited has successfully raised A$2 million through a share placement, positioning itself to accelerate exploration and expand its mining services operations.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Firebird Metals has received a significant Expression of Interest from Taza Metal Technologies to purchase up to five of its energy-efficient kilns, potentially generating over US$10 million in revenue. This marks a key step in Firebird’s international commercial expansion and highlights its leadership in sustainable manganese processing technology.

Aurum Resources has announced a substantial 50% increase in the gold resource at its Boundiali Project in Côte d'Ivoire, lifting the total group resources to 3.28 million ounces. This milestone reflects successful drilling campaigns and sets the stage for further development.

FireFly Metals has secured environmental approval and reported exceptional metallurgical results for its Green Bay Copper-Gold Project in Canada, setting the stage for a production restart. With economic studies underway and strong funding, the project is rapidly advancing toward a scoping study release in early 2026.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.